All Schrödinger offices worldwide will be closed for the week of August 17-21 as part of a company-wide initiative to rest and recharge. Please expect limited responses during this time. Scientific and Technical Support team members will be available to answer emergency support issues only.

NOV 18, 2021

SARS-CoV-2 main protease inhibitors: Physics-based approaches to the discovery of COVID-19 antivirals

Speaker:

Abba Leffler
Senior Principal Scientist

Abstract:

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Worldwide, there have been over 240 million cases reported and close to 5 million deaths. Even though there are now several vaccines available for the disease, there is a clear need for the development of small molecule antivirals. One approach to the rapid discovery of such therapeutics is to apply physics-based methods to structures of the SARS-CoV-2 main protease, a key enzyme in the viral replication process. This talk will focus on the medicinal and computational chemistry driven discovery of main protease inhibitors. The challenges of coordinating this multi-company effort, the use of WaterMap to guide the design of inhibitors, and the use of Free-Energy Perturbation (FEP+) to predict the potencies of compounds to prioritize them for synthesis will be discussed. Biological results for key compounds will be presented.